Haley Mease, NP
Family · Branson, MONPI 1528637873
Payments from drug & device makers
Across 241 payments — averaging $16.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$737
- Novo Nordisk$609
- Dexcom, Inc.$535
- Lilly USA, LLC$275
- Radius Health, Inc.$211
- Sanofi-aventis U.S. LLC$204
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,989100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 55 | $737 |
| Novo Nordisk | 43 | $609 |
| Dexcom, Inc. | 31 | $535 |
| Lilly USA, LLC | 16 | $275 |
| Radius Health, Inc. | 10 | $211 |
| Sanofi-aventis U.S. LLC | 12 | $204 |
| Bayer | 12 | $188 |
| Globus Medical | 7 | $178 |
| Novartis | 11 | $177 |
| Ascendis Pharma Endocrinology Inc | 7 | $141 |
| Xeris Pharmaceuticals, Inc. | 7 | $120 |
| Insulet Corporation | 2 | $79 |
| Corcept Therapeutics | 5 | $78 |
| Boehringer Ingelheim | 3 | $62 |
| Antares Pharma, Inc. | 3 | $57 |
| Tandem Diabetes Care, Inc. | 3 | $48 |
| Eisai Inc. | 2 | $41 |
| IBSA Pharma Inc. | 2 | $35 |
| Madrigal Pharmaceuticals | 1 | $29 |
| Intuity Medical Inc | 1 | $24 |
| BETA Bionics, Inc. | 1 | $23 |
| Alvogen Inc | 1 | $23 |
| Recordati_rare_diseases_inc. | 1 | $23 |
| Sequel Med Tech, LLC | 1 | $23 |
| Halozyme Inc | 1 | $20 |
| AstraZeneca | 1 | $20 |
| Medtronic | 1 | $15 |
| AbbVie | 1 | $14 |
How this compares
$3,989 in reported general payments places this provider in the 90th percentile of 3,812 family providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 518 | $716,102 |
| JardianceEmpagliflozin | 562 | $551,438 |
| TrulicityDulaglutide | 165 | $245,697 |
| MounjaroTirzepatide | 162 | $190,556 |
| FarxigaDapagliflozin Propanediol | 158 | $152,573 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 167 | $150,707 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 68 | $72,607 |
| Tresiba Flextouch U-100Insulin Degludec | 69 | $63,643 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 68 | $60,135 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 65 | $55,688 |
| RybelsusSemaglutide | 28 | $53,768 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 303 | $48,116 |
| Novolog FlexpenInsulin Aspart | 143 | $44,135 |
| Tresiba Flextouch U-200Insulin Degludec | 32 | $40,506 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 19 | $38,002 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6, Novolog | $609 | $814,925590 claims |
| Boehringer IngelheimJardiance, Tradjenta | $62 | $568,485576 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $275 | $443,875350 claims |
| AstraZenecaFarxiga | $20 | $152,573158 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $204 | $150,707167 claims |
| Radius Health, Inc.Tymlos | $211 | $34,03011 claims |
| AbbVieSynthroid, Savella | $14 | $9,937114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,812 family providers in Missouri.
Other family in Branson
- Hollie HolderfieldBranson$13K
- Connie SpencerSaint Joseph$320K
- Shayla SandersKansas City$306K
- Tamera WolfLees Summit$215K
- Tiffany ArnoldFestus$177K
- Tiffany NelsonSedalia$164K
- Chelsey BeckerSaint Peters$104K
- Carey PattonDes Peres$94K
- Marcy MarkesColumbia$92K
- Laura HedigerSpringfield$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.